Evidence map›Paper›PMID 40603305›Full record

ArticleNature communications2025

SPA-PNN ligand for the kinetic resolution of carbocyclic and heterocyclic spiranes by asymmetric hydrogenation.

Yong-Yao Li, Ka Lu, Ju-Song Yang, Xiao-Ming Zhang, Fu-Min Zhang, Yong-Qiang Tu

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yong-Yao LiState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Ka LuState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Ju-Song YangState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Xiao-Ming ZhangState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.ORCID http://orcid.org/0000-0002-9294-9672
Fu-Min ZhangState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China. zhangfm@lzu.edu.cn.ORCID http://orcid.org/0000-0001-5578-1148
Yong-Qiang TuState Key Laboratory of Applied Organic Chemistry & College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China. tuyq@lzu.edu.cn.ORCID http://orcid.org/0000-0002-9784-4052

Funding

National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund) 22278200National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund) 22371100National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund) 92256303
6 · The paper itself

Abstract

The chiral carbocyclic and heterocyclic spirane scaffolds are widely present in natural products and pharmaceutical molecules. Efficient, concise, and enantioenriched synthesis of these structures is a significant objective in both academic and industrial fields. Here, we design and synthesize a series of chiral SPA-PNN ligands, which are used to kinetically resolve racemic spirocyclic 1,3-diketones and their analogs via Ir-catalyzed asymmetric direct hydrogenation to afford the corresponding chiral spirocyclic 1,3-diketones and chiral hydroxyspiroketones. This asymmetric transformation features broad substrate scope (four different types of spirocycle), low catalyst loading (S/C = 5000), and an excellent kinetic resolution efficiency (selectivity factor of up to 207). Notably, the resulting chiral products are successfully used in the total and formal synthesis of four natural products, and in the preparation of key synthetic intermediates for structurally attractive ligands. Furthermore, control experiments and DFT calculations enable the origin of the observed enantioselectivity to be elucidated.

Identifiers

PMID40603305
PMCPMC12222460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.